Top Tweets for #CoMyDAL
Outstanding talk by Professor @SKordasti in #IACH2025 #ComyDAL meeting in Paris on immune targeting in #MDSsm
Best team leading IACH dayS in paris #colym #comydal #mpncod @AnnaSureda5 @Dr_AmerZeidan @Mohty_EBMT and Arnon Nagler
CONGRESS | #IACH23 | #CoMyDAL @SridharChaganti, @uhbtrust discusses the role of CAR T-cell therapy in ALL and the indications for transplantation according to cytogenetics, MRD risk, relapsed disease, and post CAR T-cell therapy #allsm #leusm #medicalcongress
CONGRESS | #IACH23 | #CoMyDAL
Nicola Goekbuget, @goetheuni presents clinical data on the treatment of T-ALL using GMALL protocols highlighting the need for standardized classification systems and improved treatment options for R/R T-ALL #allsm #leusm
#IACH23 | #CoMyDAL Elias Jabbour,
@MDAndersonNews delivers an interesting talk on the management of Ph-positive ALL, highlighting whether we still need allo-SCT, high efficacy of ponatinib, & new therapies such as olverembatinib currently being explored in this setting #allsm
CONGRESS | #IACH23 | #CoMyDAL Robin Foà @SapienzaRoma gave a presentation on Ph-negative ALL highlighting the key role of MRD monitoring and immunotherapies such as blinatumomab on clinical outcomes
#allsm #leusm
@MSubklewe with a tour-de-force talk on new directions & challenges of immune therapies in #AMLsm & #MDSsm @TheIACH #COMyDAL
@KlausMetzelerMD giving a fantastic talk on resistance mechanics to novel therapies in @IACH #COMyDAL
CONGRESS | #IACH23 | #CoMyDAL
Naval Daver @Daver_Leukemia @LeukemiaMDA reviews firstline therapies for fit patients on behalf of Jessica Altman @jaltmanmd.
· Value of molecular MRD in getting data quickly, and potential to include NGS in regulatory endpoints
· Transplant decisions are dynamic
· Promising trial results of FLAG-Ida-Ven
· High interest in FLT3i including quizartinib, and exciting Aza-ven plus gilteritinib data
@TheIACH #IACH2023 #AMLsm
CONGRESS | #IACH23 | #CoMyDAL
Thomas Cluzeau @thomas_cluzeau @Univ_CotedAzur shares his thoughts on the most promising agents in development:
· IMGN632 plus Aza-Ven backbone
· Gilteritinib plus Aza-Ven backbone
· Magrolimab in TP53m AML
@TheIACH #IACH2023 #amlsm
CONGRESS | #IACH23 | #CoMyDAL
Marion Subklewe @subklewe @LMU_Muenchen describes current immunotherapy landscape in AML and challenges, including target antigen choice. She covers GO as the only currently approved option, antibody-based agents and the need for step-up dosing to mitigate CRS, bispecifics including pre-clinical models with Ven-Aza, and the future of CAR T and NK cells.
@TheIACH #IACH2023 #AMLsm
CONGRESS | #IACH23 | #CoMyDAL
Gail Roboz @WCMLeukemia @nyphospital asks whether adding more agents is better?
· Additive strategy for FLT3 inhibitors on top of baseline agents
· Triplets may not add everywhere, patient decision making needed
· Power triplets and suggestions for OS benefit with FLAG-Ida+Ven, ClIA+Ven
· Unable to do all the randomized studies needed for all patient subgroups and drug combinations
· Excitement over potential menin inhibitor triplets with low and intensive chemo
@TheIACH #IACH2023 #AMLsm
CONGRESS | #IACH23 | #CoMyDAL
Andrew Wei, @PeterMacCC, presents the challenges of treating R/R AML, highlighting 5yr survival still < 10%. He runs through current and potential future therapeutic options, querying what treatment might look like with all the new firstline agents?
@TheIACH #IACH2023 #AMLsm
Outstanding panel discussions on all aspects of #MDSsm in @TheIACH #COMyDAL meeting. What a true pleasure to co-chair the meeting with the one & only dr @Santin13Valeria & have such amazing faculty join us for very robust discussions & debates on how to move the field forward
CONGRESS | #IACH23 | #CoMyDAL
Raphael Itzykson @raphaelitzykson @HopSaintLouis talks describes the need for a clear definition of MDS/AML. He describes therapeutic strategies including the benefit seen with CPX-351 in patients with MDS-type mutations and the potential of HMA+Ven.
@TheIACH #IACH2023 #AMLsm #MDSsm
Last Seen Hashtags on Sotwe
haikunotbyme
Seen from United States
minichat
Seen from Australia
PatisserieVegetale
Seen from United States
minichat()*******************************************************************************************
Seen from United States
페티쉬
Seen from Korea
sloppy head ebony
Seen from United States
Omarielis
Seen from United States
بوسي_الرقاصة
Seen from Egypt
gay ai teen
Seen from Peru
workouttomorrow
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.8M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers